New drugs for asthma, allergy and COPD
Author(s)
Bibliographic Information
New drugs for asthma, allergy and COPD
（Progress in respiratory research, v. 31）
Karger, c2001
Available at 7 libraries
Note
Includes bibliographical references and indexes
Description and Table of Contents
Description
This book provides a state-of-the-art account by academic respiratory physicians and senior pharmaceutical industry personnel on the development of new drugs for asthma, allergy and COPD. It contains 80 chapters of highly condensed information, presented in an attractive, reader-friendly format with much use of tables, figures and diagrams. In addition to summarizing the diverse range of current approaches, this handbook also looks into the future, considering many topics that are promising, but have only emerged in the last few years. Developments within established drug categories such as beta-2-agonists, steroids and leukotriene antagonists are also reviewed. Never before has a single book brought together so many pharmaceutical drug developers sharing their experience on such a wide range of respiratory topics!
Table of Contents
- general aspects: the need for new therapy
- current therapy for asthma
- current therapy for COPD
- pharmacogenetics
- delivery of biologics to the lung
- immunopathology - comparison of COPD and asthma
- monitoring lung function
- airway hyperresponsiveness
- airways remodelling
- exhaled breath analysis
- clinical studies on new drugs. Bronchodilators: bronchodilators - an overview
- long-acting beta2-agonists
- single-isomer beta-agonists
- dual D2 dopamine receptor and beta2-adrenoceptor agonists for the modulation of sensory nerves in COPD
- anticholinergics - tiotropium
- potassium channel openers - agents for the treatment of airway hyperreactivity
- urodilatin. Steroids: steroids - an overview
- ciclesonide - an on-site-activated steroid
- soft steroids
- dissociated steroids
- oestradiol metabolites - effects on airway remodelling. Leukotriene inhibitors: leukotriene inhibitors - an overview
- cysteinyl leukotriene antagonists
- 5-lipoxygenase inhibitors
- LTB4 antagonism. Mediator inhibitors and agonists: H1-antihistamines
- histamine H3 antagonists
- kinin receptor antagonists
- endothelin antagonists
- tachykinin antagonists
- antioxidants
- selective iNOS inhibitors
- mucus regulation
- P2Y receptor agonists - role in mucosal hydration and mucociliary clearance. Protease inhibitors: tryptase inhibition
- neutrophil elastase inhibitors
- macrophage metalloelastase inhibitors. Allergen- and IgE-directed therapies: allergen, IgE and mast-cell-directed responses - an overview
- allergen immunotherapy
- peptide immunotherapy
- recombinant allergens
- anti-IgE antibody
- CD23. Cell immunomodulation: cell immunomodulation - an overview
- costimulatory molecules in T cell activation
- GATA-3 - a Th2-selective target
- mycobacterial immunization - agents to limit asthma
- CpG oligodeoxynucleotides
- CD8 T cells - potential therapeutic targets?
- macrocyclic immunosuppressants. Cytokine-directed therapy: cytokines - an overview
- TNF antagonism
- GM-CSF antagonists
- interleukin-4 antagonism
- interleukin-13 antagonism
- interleukin-5 antagonism: interleukin-10
- interleukin-12, interleukin-18 and interferon-gamma. Chemokine receptor inhibition: chemokines - an overview
- chemokine receptors on Th1 and Th2 cells
- CCR-3 antagonists
- interleukin-8 receptor (CXCR2) antagonists. Adhesion molecule inhibitors: adhesion molecule antagonism - an overview
- small-molecule VLA-4 antagonists
- selectin antagonists - therapeutics for airway inflammation
- ICAM-1 and VCAM-1 antagonists. Inhibition of cell signalling: eosinophil G-protein-coupled receptor signalling - an overview
- phosphodiesterase-4 inhibitors. Therapies acting on transcription: therapies acting on transcription - an overview
- chromatin modification
- activator protein-1 and nuclear factor-kappa B
- inhibition of p38 MAP kinase
- STAT6 - role in IL-4-mediated signalling
- retinoids. Genetic therapy: asthma and COPD genetics and genomics - an overview
- respirable antisense oligonucleotides
- antisense therapy
- ribozyme therapy
- gene therapy.
by "Nielsen BookData"